Emerging research suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , could provide a promising advancement for body management . Initial patient investigations have shown impressive decreases in visceral fat , conceivably outperforming other weight-loss therapies . Despite this, more evaluation is needed to fully determine its lo